Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
No Placebo
Drugs
Locations
Clinical Specialty
2221-2240 of 2,251 trials

Advanced Solid Tumors: S095035 Treatment Study

We are investigating the safety and effectiveness of S095035, alone and with TNG462, for adults with advanced solid tumors that have a specific genetic deletion. This study aims to find the best dose and assess how well the treatment works.

Malignant Solid TumorSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesPartially RemoteOncology

Atrial Fibrillation: Early Rhythm-Control Therapy for Stroke Prevention

We are studying if starting rhythm-control therapy early helps patients with atrial fibrillation after a stroke avoid further heart problems. This trial also examines the impact on quality of life and treatment costs.

Acute Ischemic Stroke and Atrial Fibrillation>2 yearsMonitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesPartially RemoteCardiologyInternal Medicine

Gastrointestinal Tumors: OncoGreen Imaging Study

We are testing a new imaging technique using OncoGreen to help surgeons better visualize tumors during surgery. This study is for patients with gastrointestinal tumors who are having surgery to remove their tumors.

Digestive System Tumors>2 yearsSafety phase (I)Efficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesGastroenterologyInternal MedicineOncology

Atrial Fibrillation: Amiodarone Administration Study

We are comparing intravenous and enteral amiodarone in critically ill patients with new-onset atrial fibrillation. The goal is to see which method is more effective in restoring normal heart rhythm and improving overall health.

Atrial Fibrillation with Rapid Ventricular Response≤3 monthsMonitoring phase (IV)No PlaceboInvestigational MedicinesCardiologyInternal Medicine

Lactose Intolerance Diagnosis: LacTEST for Children

We are studying the LacTEST to see if it accurately diagnoses lactose intolerance in children aged 5 to 11. The trial will also check the test's safety and whether a shorter urine collection time is effective.

Lactose Intolerance≤3 monthsMonitoring phase (IV)≤5 visitsNo PlaceboInvestigational MedicinesPartially RemoteGastroenterologyPediatrics

Chikungunya Vaccine: Effectiveness and Safety Study

We are evaluating how well the chikungunya vaccine works in preventing severe disease and hospitalizations in at-risk populations. This study aims to understand the vaccine's real-life impact on health outcomes.

Chikungunya1-2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesInfectious Diseases

Durvalumab for Limited Stage Small Cell Lung Cancer

We are studying the safety and effectiveness of durvalumab for patients with limited stage small cell lung cancer who have not progressed after chemoradiation therapy. This trial also looks at how the treatment affects quality of life and disease symptoms.

Small Cell Lung Cancer>2 yearsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesOncology

Colonoscopy Prep: Mannitol vs. Plenvu®

We are studying whether mannitol is as effective and acceptable as Plenvu® for bowel preparation before a colonoscopy. This trial aims to ensure patient comfort and safety during the procedure.

Colonoscopy3-6 monthsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteGastroenterology

Covert Brain Infarction: Antiplatelet and Lipid-Lowering Treatments

We are studying whether adding antiplatelet and cholesterol-lowering medications can help patients with covert brain infarctions reduce serious health risks. This trial will also assess the impact on cognitive health and overall mortality.

Covert Brain Infarct>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesPartially RemoteCardiologyNeurology

Gastric Cancer: Intraperitoneal Irinotecan Study

We are exploring a new treatment combining intraperitoneal irinotecan with standard therapy for patients with gastric cancer that has spread to the abdomen. This study aims to evaluate its safety, effectiveness, and impact on quality of life.

Gastric Peritoneal Metastases>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesCost ReimbursementOncology

Immunotherapy for High-Risk Oral Disorders: APHRODITE Trial

We are testing a new immunotherapy to see if it can prevent high-risk oral disorders from turning into cancer. The study will also look at the treatment's safety and its effects on patients' quality of life.

Oral Disorders>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesPartially RemoteOncologyOtolaryngology

Long-term Safety Study of GD2IL18CART Treatment

We are following up with patients who received GD2IL18CART to check for any long-term safety concerns and to see how well the treatment is working over time, especially in children.

NeuroblastomaOsteosarcomaEwing's Sarcoma>2 yearsSafety phase (I)No PlaceboInvestigational MedicinesOncology

Leriglitazone: Drug Interaction Study

We are studying how the new drug leriglitazone interacts with other medications and food in healthy men. This research may help us understand its safety and effectiveness when taken with certain drugs or after a high-fat meal.

AdrenoleukodystrophySafety phase (I)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesInternal MedicineNeurology

IgA Nephropathy: Atacicept Treatment Study

We are testing a new medication, atacicept, to see if it helps patients with IgA nephropathy by reducing a specific protein in the blood. We will also monitor its safety and how it affects other immune factors.

IgA Nephropathy (Berger's Disease)1-2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesNephrology

Cangrelor for Acute Ischemic Stroke Treatment

We are studying the safety and effectiveness of an intravenous medication called Cangrelor for patients with acute ischemic stroke and significant carotid artery blockage. This trial aims to see if it helps improve blood flow during emergency stenting procedures.

Ischemic Stroke with Large Artery Occlusion>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteCardiologyNeurology

Vormatrigine for Adults with Epilepsy

We are studying the safety and tolerability of vormatrigine in adults with focal or generalized tonic-clonic seizures. We also aim to explore its effects on seizure frequency and overall patient experience.

Focal Epilepsy and Tonic-Clonic EpilepsyConfirmation phase (III)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteNeurology

TAR-0520 Gel for Preventing Nerve Damage in Breast Cancer Patients

We are studying whether TAR-0520 Gel can safely prevent nerve damage and nail changes in patients receiving taxane chemotherapy for breast cancer.

Chemotherapy-Induced Peripheral Neuropathy6-12 monthsEfficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesInternal MedicineNeurologyOncology

Zoldonrasib for RAS G12D-Mutant Non-Small Cell Lung Cancer

We are studying the effects of zoldonrasib in patients with RAS G12D-mutant non-small cell lung cancer who have been previously treated. The goal is to see how well it works and how safe it is compared to existing treatments.

Non-small Cell Lung Cancer>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementOncologyPulmonology

Advanced Solid Tumors: MK-1084 Treatment Study

We are studying the effects of MK-1084, both alone and with cetuximab, in patients with advanced solid tumors that have a KRAS G12C mutation. The goal is to see how well these treatments work and how safe they are.

Malignant Neoplasm with KRAS G12C Mutation>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesOncology

Type 2 Diabetes: SGLT-2 Inhibitors and Heart Health

We are studying how SGLT-2 inhibitors may improve heart function and nerve health in people with type 2 diabetes. This research aims to understand the connection between these medications and heart regulation.

Type 2 DiabetesMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesCardiologyEndocrinologyNeurology